• Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues


Hospira Plans $120 Million Expansion Project At Its McPherson, Kansas, Production Center

Hospira Inc., the world’s leading provider of injectable drugs and infusion technologies, will make $120 million in capital improvements, during the next five years, at its facility in McPherson, Kansas, with plans to create 150 jobs.

As part of the McPherson investment, Hospira will be completing capital improvement and modernization projects, including expanding capacity, adding automated visual inspection systems and installing additional production lines at the facility.

“Our operations in McPherson are critical to ensuring that Hospira continues to supply high-quality, more affordable medicines to patients who need them,” said Andrew Knudten, Vice President, McPherson Operations, Hospira. “This investment enables us to support a sustainable output of important injectable medications and advance growth opportunities at the plant and in our community. It is also a testament to the dedication of our McPherson employees, the commitment of the community and the appreciated support from the state of Kansas.”

“Hospira’s investment in McPherson is good news for the community and the Kansas economy,” said Governor Sam Brownback. “Kansas has built a strong pro-growth business environment that supports the hard work of companies such as Hospira.”

According to the Kansas Department of Commerce, Hospira has a strong heritage in McPherson that dates back to 1977. The McPherson plant has approximately 1,400 employees and produces generic injectable and biologic medicines using advanced manufacturing technology, including lyophilization, isolator filling lines and state-of-the-art aseptic filling processes. The McPherson team provides medications in multiple delivery systems, including glass vials, ampoules, syringes and cartridges, and makes products for One 2 One, Hospira's industry-leading pharmaceutical contract manufacturing business.


Exclusive Research